BB BIOTECH AG Business report
Business Report | 4-24 |
Performance/Multi-year comparison | 5 |
Shareholder letter | 10 |
Portfolio Update Q4 2021 | 14 |
Portfolio at a glance | 17 |
Outlook | 18 |
Top Story | 23 |
5 | BB Biotech Annual Report 2021 - Business Report |
Performance/Multi-year comparison
6BB Biotech Annual Report 2021 - Business Report
Indexed performance since launch
BB Biotech AG (SIX)-CHF
0
NAV CHF indexed Share Price CHF indexed Nasdaq Biotech Index (NBI) TR indexed
Annual performance | Cumulated performance | |||||||
31.12.2021 | 31.12.2021 | |||||||
SHARE | NAV | NBI TR | SHARE | NAV | NBI TR | |||
2021 | 8.3% | (11.5%) | 3.0% | 1 year | 8.3% | (11.5%) | 3.0% | |
2020 | 19.3% | 24.3% | 15.8% | 3 years | 53.3% | 35.7% | 46.7% | |
2019 | 18.5% | 23.4% | 23.0% | 5 years | 78.6% | 43.3% | 57.1% | |
2018 | (5.2%) | (14.5%) | (8.0%) | since inception 1) | 3 095% | 2 278% | 1 397% | |
2017 | 22.9% | 23.4% | 16.4% | 1 | 09.11.1993 | |||
Annualized performance
31.12.2021
SHARE | NAV | NBI TR | |
1 year | 8.3% | (11.5%) | 3.0% |
3 years | 15.3% | 10.7% | 13.6% |
5 years | 12.3% | 7.4% | 9.4% |
since inception 1) | 13.1% | 11.9% | 10.1% |
1 09.11.1993
7 | BB Biotech Annual Report 2021 - Business Report |
BB BIOTECH AG (XETRA)-EUR
0
NAV EUR indexed Share Price EUR indexed Nasdaq Biotech Index (NBI) TR indexed
Annual performance | Cumulated performance | |||||||
31.12.2021 | 31.12.2021 | |||||||
SHARE | NAV | NBI TR | SHARE | NAV | NBI TR | |||
2021 | 13.3% | (7.8%) | 7.4% | 1 year | 13.3% | (7.8%) | 7.4% | |
2020 | 18.1% | 24.8% | 16.1% | 3 years | 65.4% | 47.4% | 59.1% | |
2019 | 23.4% | 28.1% | 27.6% | 5 years | 82.4% | 47.3% | 65.5% | |
2018 | (2.2%) | (11.1%) | (4.3%) | since inception 1) | 2 556% | 1 889% | 1 416% | |
2017 | 12.9% | 12.5% | 6.7% | 1 | 10.12.1997 | |||
Annualized performance
31.12.2021
SHARE | NAV | NBI TR | ||
1 year | 13.3% | (7.8%) | 7.4% | |
3 years | 18.2% | 13.8% | 16.7% | |
5 years | 12.8% | 8.1% | 10.2% | |
since inception 1) | 14.6% | 13.2% | 12.0% | |
1 | 10.12.1997 |
8 | BB Biotech Annual Report 2021 - Business Report |
BB BIOTECH AG (MILAN)-EUR
0
NAV EUR indexed Share Price EUR indexed Nasdaq Biotech Index (NBI) TR indexed
Annual performance | Cumulated performance | |||||||
31.12.2021 | 31.12.2021 | |||||||
SHARE | NAV | NBI TR | SHARE | NAV | NBI TR | |||
2021 | 13.0% | (7.8%) | 7.4% | 1 year | 13.0% | (7.8%) | 7.4% | |
2020 | 19.7% | 24.8% | 16.1% | 3 years | 65.9% | 47.4% | 59.1% | |
2019 | 22.6% | 28.1% | 27.6% | 5 years | 83.7% | 47.3% | 62.5% | |
2018 | (1.3%) | (11.1%) | (4.3%) | since inception 1) | 516% | 359% | 197% | |
2017 | 12.2% | 12.5% | 6.7% | 1 | 19.10.2000 | |||
Annualized performance
31.12.2021
SHARE | NAV | NBI TR | ||
1 year | 13.0% | (7.8%) | 7.4% | |
3 years | 18.4% | 13.8% | 16.7% | |
5 years | 12.9% | 8.1% | 10.2% | |
since inception 1) | 8.9% | 7.4% | 5.3% | |
1 | 19.10.2000 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
BB Biotech AG published this content on 18 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 February 2022 06:10:04 UTC.
